Concord Drugs Ltd
Concord Drugs Ltd (CONCORD) last reported results for the quarter ended Jun 2026, with sales of ₹20.95 crore and net profit of ₹1.11 crore. The stock last traded at ₹74, a market capitalisation of ₹97.5 crore, on a P/E of 47.6. Over the past 52 weeks the stock has ranged between ₹61 and ₹92.5. Figures are as of 6 Oct 2026 and are not real time.
Concord Drugs Ltd share price and key metrics
- Current price
- ₹74
- Market cap
- ₹97.5 cr
- Stock P/E
- 47.6
- Book value
- ₹36.8
- ROE
- 2.57%
- ROCE
- 5.46%
- Dividend yield
- 0.00%
- 52w high / low
- 92.5/61.0
Metrics as of 6 Oct 2026. Not real time.
Track Concord Drugs Ltd
Cruxal reads every Concord Drugs Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Concord Drugs Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 15%
- TTM
- 83%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 2%
- TTM
- 377%
- 10 Years
- 3%
- 5 Years
- 19%
- 3 Years
- 31%
- 1 Year
- 13%
- 10 Years
- %
- 5 Years
- 3%
- 3 Years
- 2%
- Last Year
- 3%
Concord Drugs Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹20.95 cr, up 53.9% from ₹13.61 cr a year earlier. Net profit was ₹1.11 cr, up 825.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 12.37 | 10.8 | 10.39 | 13.61 | 10.28 | 16.99 | 37.9 | 20.95 |
| Expenses | 11.49 | 9.4 | 9.34 | 12.59 | 9.18 | 16.05 | 36.4 | 18.66 |
| Operating profit | 0.88 | 1.4 | 1.05 | 1.02 | 1.1 | 0.94 | 1.5 | 2.29 |
| OPM % | 7.11% | 12.96% | 10.11% | 7.49% | 10.70% | 5.53% | 3.96% | 10.93% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0.47 | 0.5 | 0.61 | 0.49 | 0.49 | 0.34 | 0.4 | 0.4 |
| Depreciation | 0.34 | 0.37 | 0.38 | 0.37 | 0.34 | 0.31 | 0.35 | 0.35 |
| Profit before tax | 0.07 | 0.53 | 0.06 | 0.16 | 0.27 | 0.29 | 0.75 | 1.54 |
| Tax % | 42.86% | 58.49% | 33.33% | 25.00% | 29.63% | 27.59% | 29.33% | 27.92% |
| Net profit | 0.04 | 0.23 | 0.04 | 0.12 | 0.19 | 0.22 | 0.53 | 1.11 |
| EPS (₹) | 0.04 | 0.23 | 0.04 | 0.12 | 0.19 | 0.17 | 0.40 | 0.84 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Concord Drugs Ltd annual results
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|
| Sales | 58.96 | 52.08 | 44.92 | 45.24 | 78.74 | 86.12 |
| Operating profit | 5.59 | 4.57 | 4.04 | 4.14 | 4.52 | 5.83 |
| OPM % | 9.48% | 8.77% | 8.99% | 9.15% | 5.74% | 6.77% |
| Net profit | 1.59 | 0.99 | 0.47 | 0.34 | 1.06 | 2.05 |
| EPS (₹) | 1.82 | 1.06 | 0.47 | 0.34 | 0.80 | 1.60 |
TTM is the trailing twelve months to the most recent quarter.
Concord Drugs Ltd balance sheet
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity capital | 8.74 | 9.32 | 10.00 | 10.00 | 13.18 |
| Reserves | 19.62 | 22.38 | 23.82 | 24.11 | 35.34 |
| Borrowings | 16.43 | 16.96 | 17.52 | 19.24 | 14.51 |
| Other liabilities | 11.66 | 9.57 | 7.46 | 11.80 | 11.86 |
| Total liabilities | 56.45 | 58.23 | 58.80 | 65.15 | 74.89 |
| Fixed assets | 13.97 | 12.92 | 11.68 | 12.21 | 11.58 |
| CWIP | 0.55 | 0.92 | 1.63 | 2.00 | 2.43 |
| Investments | 0.00 | 0.89 | 0.84 | 0.80 | 0.78 |
| Other assets | 41.93 | 43.50 | 44.65 | 50.14 | 60.10 |
| Total assets | 56.45 | 58.23 | 58.80 | 65.15 | 74.89 |
As reported by the company. Total assets equal total liabilities by construction.
Concord Drugs Ltd cash flow
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash from operations | 0.77 | 1.66 | 0.79 | 3.72 | -5.75 |
| Cash from investing | -2.44 | -2.27 | -1.01 | -2.32 | -1.13 |
| Cash from financing | 1.68 | 0.62 | 0.28 | -1.43 | 7.04 |
| Net cash flow | 0.01 | 0.02 | 0.07 | -0.02 | 0.16 |
| Free cash flow | -1.69 | 0.80 | -0.23 | 1.39 | -6.92 |
| CFO / operating profit | 26% | 45% | 25% | 95% | -118% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Concord Drugs Ltd operating ratios
| Per year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROCE % | — | 6.31% | 4.98% | 5.20% | 5.46% |
| Debtor days | 141.52 | 110.80 | 103.44 | 109.73 | 113.01 |
| Inventory days | 151.64 | 178.58 | 251.53 | 261.81 | 137.69 |
| Days payable | 62.25 | 46.92 | 34.02 | 78.95 | 38.15 |
| Cash conversion cycle | 230.90 | 242.47 | 320.95 | 292.59 | 212.56 |
| Working capital days | 112.48 | 152.43 | 132.77 | 124.01 | 145.97 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Concord Drugs Ltd shareholding pattern
Promoters held 45.08% at Jun 2026, down from 54.39% at Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 54.39% | 54.39% | 54.39% | 54.39% | 54.39% | 54.39% | 54.39% | 45.08% |
| Public | 45.61% | 45.61% | 45.61% | 45.61% | 45.61% | 45.61% | 45.61% | 54.92% |
| No. of shareholders | 5,073 | 5,073 | 5,252 | 5,189 | 4,718 | 4,597 | 4,464 | 4,435 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Concord Drugs Ltd corporate filings
- Corporate Scrutinizer Reports Reveal Multiple Resolutions Passed at AGM with Near-Complete Voting SupportAGM/EGMhigh impact
Cruxal's analysis: Concord Drugs Limited held its 31st AGM on 30.09.2026 via video conference, with detailed…
Read the full analysis - Concord Drugs Limited Conducts 31st AGM on 30.09.2026; No financial impact disclosedAGM/EGMlow impact
Cruxal's analysis: Concord Drugs Limited held its 31st Annual General Meeting on 30.09.2026 via video…
Read the full analysis - Closure of trading WindowInsider Trading / SASTlow impact
- Concord Drugs Limited Announces 31st Annual General Meeting for September 30, 2026Company Updatelow impact
Cruxal's analysis: Concord Drugs Limited has issued an intimation regarding its 31st Annual General Meeting…
Read the full analysis - Concord Drugs Ltd issues letter to shareholders regarding regulatory complianceCompany Updatelow impact
Cruxal's analysis: Concord Drugs Ltd has issued a letter to its members in accordance with Regulation…
Read the full analysis - Concord Drugs Limited announces Book Closure and Record Date for 31st Annual General MeetingCorp. Actionlow impact
Cruxal's analysis: Concord Drugs Limited has notified the exchange regarding the closure of its Register of…
Read the full analysis - Concord Drugs Ltd files 31st Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Concord Drugs Ltd has submitted its 31st Annual Report in compliance with Regulation…
Read the full analysis - Concord Drugs Limited Announces 31st Annual General Meeting for September 30, 2026AGM/EGMlow impact
Cruxal's analysis: Concord Drugs Limited has scheduled its 31st Annual General Meeting (AGM) for September…
Read the full analysis - Concord Drugs Limited Announces 31st AGM Details and Key Board Re-appointmentsOtherslow impact
Cruxal's analysis: Concord Drugs Limited has scheduled its 31st Annual General Meeting for 30 September…
Read the full analysis - Concord Drugs Limited Reports Q1 FY2027 Financial Results with Significant YoY Revenue and Profit GrowthCompany Updatehigh impact
Cruxal's analysis: Concord Drugs Limited has released its unaudited financial results for the quarter ended…
Read the full analysis - Concord Drugs Limited reports strong Q1 FY2027 performance with significant YoY profit growthBoard Meetinghigh impact
Cruxal's analysis: Concord Drugs Limited reported a robust performance for the quarter ended 30 June 2026…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.